Oncolytics Biotech

Last updated: January 20, 2024

Brad Thompson, CEO
Brad Thompson, CEO
Country: Canada | Funding: $100.1M (+)

Website: https://www.oncolyticsbiotech.com/

Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.